Cargando…
Pharma partnering: other people’s science
Partnering is an ideal field if someone is seeking to move from a scientific to a more business-oriented discipline. Partnering’s goal is to identify and acquire external innovation. These discoveries are then included in a company’s pipeline and help bring novel treatments to patients. Advanced sci...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The American Society for Cell Biology
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5221633/ https://www.ncbi.nlm.nih.gov/pubmed/28035041 http://dx.doi.org/10.1091/mbc.E16-07-0512 |
_version_ | 1782492855261986816 |
---|---|
author | Hofmann, Christian |
author_facet | Hofmann, Christian |
author_sort | Hofmann, Christian |
collection | PubMed |
description | Partnering is an ideal field if someone is seeking to move from a scientific to a more business-oriented discipline. Partnering’s goal is to identify and acquire external innovation. These discoveries are then included in a company’s pipeline and help bring novel treatments to patients. Advanced scientific training is essential in the identification and evaluation of these external assets. Here I describe how partnering works in a pharmaceutical company and offer advice on how to make a successful transition from a PhD program to a business career. |
format | Online Article Text |
id | pubmed-5221633 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | The American Society for Cell Biology |
record_format | MEDLINE/PubMed |
spelling | pubmed-52216332017-03-16 Pharma partnering: other people’s science Hofmann, Christian Mol Biol Cell Perspectives Partnering is an ideal field if someone is seeking to move from a scientific to a more business-oriented discipline. Partnering’s goal is to identify and acquire external innovation. These discoveries are then included in a company’s pipeline and help bring novel treatments to patients. Advanced scientific training is essential in the identification and evaluation of these external assets. Here I describe how partnering works in a pharmaceutical company and offer advice on how to make a successful transition from a PhD program to a business career. The American Society for Cell Biology 2017-01-01 /pmc/articles/PMC5221633/ /pubmed/28035041 http://dx.doi.org/10.1091/mbc.E16-07-0512 Text en © 2017 Hofmann. This article is distributed by The American Society for Cell Biology under license from the author(s). Two months after publication it is available to the public under an Attribution–Noncommercial–Share Alike 3.0 Unported Creative Commons License (http://creativecommons.org/licenses/by-nc-sa/3.0). “ASCB®,” “The American Society for Cell Biology®,” and “Molecular Biology of the Cell®” are registered trademarks of The American Society for Cell Biology. |
spellingShingle | Perspectives Hofmann, Christian Pharma partnering: other people’s science |
title | Pharma partnering: other people’s science |
title_full | Pharma partnering: other people’s science |
title_fullStr | Pharma partnering: other people’s science |
title_full_unstemmed | Pharma partnering: other people’s science |
title_short | Pharma partnering: other people’s science |
title_sort | pharma partnering: other people’s science |
topic | Perspectives |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5221633/ https://www.ncbi.nlm.nih.gov/pubmed/28035041 http://dx.doi.org/10.1091/mbc.E16-07-0512 |
work_keys_str_mv | AT hofmannchristian pharmapartneringotherpeoplesscience |